Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation. It is approved in the United St...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics 2022-11, Vol.61 (11), p.1623-1639
Hauptverfasser:	Zahir, Hamim, Greenberg, Jonathan, Shuster, Dale, Hsu, Ching, Watanabe, Kengo, LaCreta, Frank
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Area Under Curve Cytochrome Cytochrome P-450 CYP3A Cytochrome P-450 CYP3A Inducers - pharmacokinetics Cytochrome P-450 CYP3A Inhibitors - pharmacology Drug dosages Drug Interactions Enzymes Esomeprazole Healthy Volunteers Hepatitis Humans Internal Medicine Itraconazole Medicine Medicine & Public Health Metabolism Metabolites NCT NCT03138759 Original Original Research Article Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Plasma Probenecid Rifampin Risk assessment Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!